EP01.01-002. Challenges in the Use of NLST Image Data for Quantitative Algorithm Development

EP01.01-003. DELFI-L101: Development of a Blood Based Assay That Evaluates Cell-Free DNA Fragmentation Patterns to Detect Lung Cancer

EP01.01-004. The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and Interleukin-23 (IL-23) in Lung Cancer

EP01.01-005. Increased Levels of mRNAs and miRNAs Associated with Imminent and Advanced Lung Cancer

EP01.01-006. Sensitive Detection of Lung Cancer Using a Multiomic Plasma Cell-Free DNA Sequencing Assay

EP01.01-007. Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients

EP01.01-009. Common MicroRNAs in Pre-diagnostic Serum Associated with Lung Cancer in Two Cohorts up to Eight Years Before Diagnosis: A HUNT Study

EP01.01-010. Graphene Based Activity Sensors Detect All Stages of Lung Cancer Using an Evolutionary Machine Learning Algorithm Approach

EP01.01-011. Utility of Arm-level cfDNA Fragment Size Distribution in the Early Detection of Lung Cancer and Pan Cancer

EP01.01-002. Clinical and Molecular Features of Chinese Early-stage Multiple Primary Lung Cancer Patients

EP01.02-001. Citizens’ Perspective on Combination Screening for Lung Cancer, COPD and CVD

EP01.02-002. Awareness of Palestinians about Lung Cancer Symptoms: A National Cross-sectional Study

EP01.02-003. Lung Cancer Screening: A Systematic Review of Knowledge Translation Interventions

EP01.02-004. Education Messages and Strategies About Lung Cancer Screening: A Systematic Review

EP01.02-005. Exploring Individuals’ Views on Invitation to Lung Cancer Screening: Developing a Tailored Approach

EP01.02-006. Excuse Me? Patient Perceptions of Lung Cancer Screening Results

EP01.02-007. It's Not How You Start, It's How You Finish: Patient Motivators to Follow Low-Dose Screening Recommendations

EP01.02-008. Pocket Nodules, An Innovative Patient Education Tool to Explain Lung Nodules

EP01.03-001. Māori Perspectives on a Potential Lung Cancer Screening Programme Aotearoa NZ: An Indigenous People’s Perspective.

EP01.03-002. Implementation of the International Lung Screen Trial (ILST) in Catalonia: A Cost Analysis study

EP01.03-003. AI Detection of Emphysema in an Ultra-Low Dose CT Lung Cancer Screening Program

EP01.03-004. Should We Screen for Lung Cancer? A 10-Country Analysis Identifying Key Decision-Making Factors

EP01.03-005. Current status of High-risk Smokers Participating in Population-based National Lung Cancer Screening Program in Korea

EP01.03-006. Potential Drivers of Lung Cancer Screening Participation in Australia: A Qualitative Study to Inform Future Implementation

EP01.03-007. Lung Cancer Screening Use Among Screening-Eligible Adults With Disability in the United States: Evidence From Population-Based Data

EP01.03-008. Lung Cancer Screening Patients Experiences and Satisfaction: Quantitative and Qualitative Findings From a Survey Study

EP01.03-009. Cost-effectiveness of Lung Cancer Screening in New Zealand Varies by Ethnicity

EP01.03-010. China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results

EP01.03-011. Clinical Features and Surgical Outcomes of Young Patients with Ground Glass Opacity Featured Lung Adenocarcinoma

EP01.03-012. Acceptability and Feasibility of Lung Cancer Screening in Australia: The View of Key Stakeholders

EP01.03-013. A Pilot Study of Lung Cancer Screening with Low Dose CT in Georgia (One Centre Experience and Preliminary Data).

EP01.04-001. A Programmatic Approach to Improve Efficiency in Lung Cancer Screening

EP01.04-002. The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program

EP01.04-003. Effectiveness of Cloud-based Computer Aided Quality Control System in Korean National Lung Cancer Screening

EP01.04-004. Overcoming the Barriers to Lung Cancer Screening using a Systemwide Approach

EP01.04-005. Quantitative Characteristics in Global CT Lung Cancer Screening Populations Using the ELIC Distributed Database and Computation Environment

EP01.04-006. Clinical Scores, Biomarkers and It Tools in Lung Cancer Screening - Can an Integrated Approach Overcome Current Challenges?

EP01.05-001. Radiomics to Increase the Effectiveness of Lung Cancer Screening Programs. Radiolung Preliminary Results

EP01.05-002. Role of the Lung Cancer Screening MDT in the Manchester Lung Health Check Programme

EP01.05-003. Changes of Repeated Lung Cancer Screening Results and Affected Factors; Analysis of Korean National Lung Cancer Screening Program

EP01.05-004. Trial in Progress: An Observational Study for Management of Lung Nodules across Latin America (DOuBLED Study)

EP01.05-005. The Accuracy of Baseline Low-dose CT Lung Cancer Screening: A Systematic Review and Meta-analysis

EP01.05-006. Influenza Season Influence on Incidence and Outcome of Nodules in the NELSON Trial

EP01.05-007. Radiomics Based Machine Learning Model for Sub-cm Lung Nodule Malignancy Diagnosis in the PanCan Screening Study

EP01.05-008. Pre-Trial Validation of a Risk Prediction Model for Pulmonary Nodules Trained on a Nested Case-Control Study with No External Cohort

EP01.05-009. Simulation-Based Sample Size Estimation for an Early Detection of Lung Cancer Clinical Utility Trial in Indeterminate Pulmonary Nodules

EP01.05-010. Using a Pattern Submodel Approach to Predict Lung Cancer in High-Risk Lung Nodule Clinics

EP01.05-011. Radiologic Features of Nodules Attached to the Mediastinal or Diaphragmatic Pleura

EP01.06-001. Lung Cancer after First Primary Breast Cancer: Risk Factors and Results of Treatment

EP01.06-002. Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungIMPACT

EP01.06-003. Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population

EP01.06-004. Eliciting Quantitative Smoking History by the Use of Natural Language Processing

EP01.06-005. Assessment of Cardiovascular Risk in the Non Screening Radically Treated Lung Cancer Cohort

EP01.06-006. Impact of Low Dose CT Screening on Cause of Death in Different Socio-Economic Groups

EP01.06-007. The Impact of Modified Screening Eligibility Criteria on Race and Sex Disparities in Lung Cancer Screening

EP01.06-008. Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis

EP01.06-009. Frequency of Lung Adenocarcinoma in Patients With Growing Nonsolid and Part-Solid Nodules With Solid Component ≤5 mm

EP01.07-001. Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial

EP01.07-002. Objectives and Design of the ACR Lung Cancer Screening CT Incidental Findings - Quick Reference Guide

EP01.07-003. Accuracy of Cytological Diagnosis for Malignant Nodule in Participants With Nonsolid Nodules and Part-Solid Nodules With Solid Component≤5 mm

EP01.07-004. FDG-PET-CT for Staging Screen Detected Lung Cancer

EP01.07-005. Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Diagnosing Indeterminate Pulmonary Nodules

EP01.07-006. Incidence and Resource Burden for the Management of CT Detected Ground Glass Opacities at a Tertiary Lung Cancer Service in the UK

EP02.01-001. Plasma Cell-Free DNA as a Point-of-Care Wellbeing Biomarker for Early-Stage Non-Small Cell Lung Cancer Patients

EP02.01-002. Development of Circulating and Tissue Biomarkers Predicting Immune Phenotype and Response to Immunotherapy in NSCLC.

EP02.01-003. Predictive Role of Novel Grading System on Adjuvant Chemotherapy in Early Resected Lung Adenocarcinoma Based on EGFR Mutation Status

EP02.01-004. Application of a Genomic Assay for Risk Stratification of Resected NSCLC in a Community Cancer Center Setting, a Pilot Study

EP02.01-005. The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma

EP02.01-006. Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Real-World Impact on Survival

EP02.01-007. Clinicopathologic and Prognostic Features of Early Resected Lung Adenocarcinoma Characterized With Uncommon EGFR Mutation

EP02.01-008. Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas

EP02.01-009. PD-L1 Expression in Biopsies and Surgical Specimens of Lung Cancer: Impact of Biopsy Methods and Neoadjuvant Therapy

EP02.01-010. Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumor Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer

EP02.01-011. Immune-related Histologic Phenotype in Pretreatment Tumor Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer

EP02.01-012. PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation

EP02.01-013. Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario

EP02.01-014. Prognostic Classification of Early-Stage Lung Cancer Using Preoperative Prealbumin and D-dimer Levels

EP02.01-015. Computer-Aided Volumetry by Multidetector Computed Tomography is Efficient for Prognostic Prediction of Early-Stage Solid Lung Cancers

EP02.01-016. Molecular Alterations and Clinical Prognostic Factors in Resectable Non-Small Lung Cancer

EP02.01-017. The Role of Adjuvant Chemotherapy for Stage II/III Lung Adenocarcinoma Based on Epidermal Growth Factor Receptor Mutation Status

EP02.01-018. EGFR Mutations Promote Lung Adenocarcinoma From Adenocarcinoma in Situ to Minimally Invasive Carcinoma to Invasive Adenocarcinoma

EP02.02-001. Genome-wide Analysis and Dynamic Changes of Human Non-small Cell Lung Carcinoma Cells After Radiation

EP02.02-002. Increased Utilization of Stereotactic Body Radiotherapy Has Decreased Treatment Disparities for Early-Stage NSCLC

EP02.02-003. Mean Lung Dose Correlates with Volume of Radiation-Induced Lung Injury in Patients Treated with SABR for Lung Cancer

EP02.02-004. Clinical Outcomes Following Photon-Based and Proton-Based Stereotactic Body Radiation Therapy for Early Stage Lung Cancer

EP02.02-005. Changes in PFT Parameters and Correlation with Symptomatic Pulmonary Toxicity Following SBRT For Early Stage Lung Cancer

EP02.02-006. Differing Doses: The Effects of Radiation Dose Calculation Algorithms on Local Control in Early-Stage Lung Cancer

EP02.02-007. Correlation between Biological Equivalent Dose and Radiological Changes after Lung Stereotactic Ablative Radiation Therapy

EP02.02-008. Transbronchial Microwave Ablation of Lung Nodules - Good Safety Profile and Promising Mid-Term Results

EP02.02-009. Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancer, Cyberknife-M6 Experience

EP02.02-010. Histology Impacts Time-to-Treatment on Lung SBRT Outcomes

EP02.03-001. The Role of Completion Lobectomy Following Sublobar Resection in Patients with T1 Non-Small Cell Lung Cancer

EP02.03-002. Impact of Society and National Guidelines on Patient Selection for Lung Cancer Surgery in the UK from 2008 to 2013

EP02.03-003. Survival of Patients with Interstitial Lung Disease Who Undergoing Lung Cancer Surgery: A Propensity Score Matching Study

EP02.03-004. Association Between Sarcopenia and Outcomes of Lung Cancer Surgery in Old-Age Patients: Interim Analysis of Prospective Cohort Study

EP02.03-005. Perioperative Factors That Predict or Are Associated With Prolonged Air Leaks After Robotic-Assisted Pulmonary Lobectomy

EP02.03-006. Oncological Outcome And Surgical Instruments in VATS Lobectomy For Early Stage Lung Cancer

EP02.03-007. Seeds of Gold. Triple Contrast Marking in Hybrid Operative Room for All-in One Diagnostic and Therapeutic Precision Surgery

EP02.03-008. Combined Robotic Assisted Thoracic Surgery (CRATS)

EP02.03-009. Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer

EP02.03-010. Intrapulmonary and Hilar Lymph Node Dissection Performed by the Surgical Team: Impact on Pathological Stage of NSCLC

EP02.03-011. Timeliness of Surgery for Early-Stage Lung Cancer: Perspectives from Surgeons and Patients

EP02.03-012. Peri-operative and Oncologic Outcomes after Robotic-Assisted Segmentectomy at a NCI-designated Cancer Center

EP02.03-013. Should Visceral Pleural Invasion Be Prognostic Factor in Early-Stage Lung Adenocarcinoma With Tumor Size 3cm or Less?

EP02.03-014. Pulmonary Segmentectomy via Minimally Invasive Open Surgery: An Analysis From a Japanese High-Volume Hospital

EP02.03-015. Fully Robotic Arm Robot Assisted Lung Surgery Exploration

EP02.03-016. Dynamics of Recurrence After Curative Resection of Non-small Cell Lung Cancer

EP02.03-017. Novel Intraoperative CT-Guided Marking Using O-Arm in Video-Assisted Thoracoscopic Surgery

EP02.03-019. T3 Non Small Cell Lung Cancer with Satellite Nodules: A Multicentric Analysis.

EP02.03-020. Patient Outcomes Following Salvage Lung Cancer Surgery Post Definitive Chemotherapy or Radiation

EP02.03-021. Uncertain Resection for Localized cN0M0 Non Small Cell-Lung Cancer: The Crucial Prognosis of Suboptimal Lymph Node Assessment

EP02.03-022. Evolution of Lung Cancer Resection Quality: A Prospective Staggered Implementation Quality Improvement Study

EP02.03-023. Decreasing Time to Definitive Therapy with MIDAS: Minimally Invasive Diagnosis and Surgery

EP02.03-024. Clinical and Prognostic Impact of Pleural Adhesions during Lung Cancer Surgery

EP02.03-025. Long-Term Oncological Outcomes and Risk Factors of Recurrence After Segmentectomy for Primary Lung Cancer

EP02.03-026. Is Ratio of Surgical Margin to Nodule Size a Prognostic Factor in Stage 1 Adenocarcinoma?

EP02.03-027. After Surgery Factors Affecting Relapse in Early Stage Non Small Cell Lung Cancer

EP02.03-028. Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumor Spread through Air Spaces

EP02.03-029. Prognostic Factors in Curative Intent Stage I lung Adenocarcinoma: Hospital's Cancer Registry Based Analysis

EP02.04-001. Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)

EP02.04-002. Synergy of Local Treatment with Pulsed Electric Fields and Anti-PD1 Checkpoint Blockade

EP02.04-003. A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases

EP02.04-004. Time to Surgery After Neoadjuvant Immunotherapy: Not a Day Too Soon

EP02.04-005. Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

EP02.04-006. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy

EP02.04-007. Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)

EP02.04-008. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis

EP02.04-009. Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC

EP02.04-010. Clinical Outcomes After Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study

EP03.01-001. Is Airflow Limitation a CausalFactor for Lung Squamous Cell Carcinoma? Evidence from Mendelian Randomization Analysis

EP03.01-002. Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations

EP03.01-003. Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)

EP03.01-004. Impact of Covid-19 Pandemic in Lung Cancer Patients in Albania

EP03.01-005. Clinicopathological Features of ROS1-rearranged Adenocarcinomas: A Single Institutional Experience Spanning Four Years From India

EP03.01-006. Familial Aggregation in Non-small Cell Lung Cancer - An Observational Study

EP03.01-007. Comprehensive Genomic Profile of Advanced Lung Cancer in a Region With the Worst Human Development Index in Brazil

EP03.01-008. Shift in Lung Cancer Stage at Diagnosis during the COVID-19 Pandemic in New York City

EP03.01-009. BrainMets-Cross-Sectional Study To Identify The Presence Of Brain Metastasis At Diagnosis Of Advanced NSCLC EGFRm in Portuguese Patients

EP03.01-010. Clinicopathological Characteristics of Non-Small Cell Lung Cancer patients in the United Arab Emirates and Correlation with Their Outcomes

EP03.01-011. Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong

EP03.01-012. Characterization of Lung Cancer in Patients With High Familial Aggregation of Cancer: Preliminary Data From the SCAN Study

EP03.01-013. Improving the Risk Estimation for Second Primary Lung Cancer after Lung Cancer by Taking Histologic Subtype into Account

EP03.01-014. Results From the BEWELL Study: Black Raspberry Nectar for the Prevention of Lung Cancer (NCT04267874)

EP03.01-015. Disease-Free Survival and Clinical Characteristics in Early-Stage NSCLC Patients From a Danish Cohort

EP03.01-016. The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration

EP03.01-017. Epidemiology of Lung Cancer in Northern Serbia During the Past Ten Years

EP04.01-001. Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience

EP04.01-002. Costs of Locoregional and Metastatic Recurrences in Patients with Resectable Stage II-III NSCLC in Spain

EP04.01-003. Is It Time for a New Paradigm in Care of Young Cancer Patients? A Retrospective Study

EP04.01-004. Interim Feedback on Pilot Public Facing Website for Cancer Clinical Trial Patient-Reported Symptom Data: Project Patient Voice

EP04.01-005. Lung Cancer Diagnosis Following Emergency Admission: Diagnostic and Therapeutic Pathways and Outcomes Within an Italian Cancer Center

EP04.01-006. A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC)

EP04.01-007. Impact of Precision Medicine Methods on First-Line Therapies in Metastatic Non-Small Cell Lung Cancer

EP04.01-008. Factors Impacting Time from Biopsy to Initiation of Treatment for Advanced NSCLC at an Academic Hospital and Affiliate Hospitals

EP04.01-009. Performance Indicators of Lung Cancer MDT at a Regional Center: Disagreements Between Trust and NLCA Data

EP04.01-010. Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience

EP04.01-011. Diagnostic Approach and Treatment of Lung Cancer Patients in Portugal: Portuguese Lung Cancer Study Group Survey

EP04.01-012. Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data

EP04.01-013. Frailty Index Predicts Treatment Outcomes in Older Adults with Lung Cancer

EP04.01-014. Adherence to Treatment Recommendations From Multidisciplinary Tumor Boards

EP04.01-015. Lung Cancer after Solid Organ Transplantation - A Claims Data Analysis

EP04.01-017. Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer

EP04.01-018. Medical Oncology and Radiation Oncology Consultation in Non-small Cell Lung Cancer (NSCLC). A Population-Based Study Using Administrative Data

EP04.01-019. Into the Wild: Assessing Acute Care for Lung Cancer Patients, A Cohort Study to Improve Cancer Care at Emergency Department

EP04.01-020. Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center

EP04.01-021. Cancer Clinical Quality Registries: A Systematic Review of the Utilisation and Effectiveness of Knowledge Translation Interventions

EP04.01-022. Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression

EP04.01-023. Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry (ANZLCR)

EP04.01-024. Influence of Lung Diagnostic Assessment Program on Health Resource Utilization in Lung Cancer in Southeastern Ontario, Canada

EP04.01-025. Implementation of Electronic Patient Reported Outcomes in Routine Cancer Care

EP04.01-026. Cone-Beam CT Guided Navigation Bronchoscopy: a Cost-Effective Modality for the Diagnosis of Pulmonary Nodules

EP04.01-027. Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis

EP04.01-029. Reduction of ER Visits of Lung Cancer Patients Through Care Interventions in Day-To-Day Clinical Service: Experience of a Thoracic Unit in Mexico

EP04.02-001. Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival

EP04.02-003. Improving Supportive Care for Patients with Thoracic Cancer

EP04.02-004. The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer

EP04.02-005. First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival

EP04.02-006. Burn-Out Syndrome: Neglected Syndrome Among Health Care Professionals Managing Lung Cancer Patients

EP05.01-001. Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity

EP05.01-002. Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy

EP05.01-003. First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area

EP05.01-004. Induction Chemoimmunotherapy before Definitive Chemoradiotherapy for Large-Volume Unresectable Locally Advanced NSCLC

EP05.01-005. Impact of Antibiotic Use Before Definitive Concurrent Chemoradiation in Patients With Locally Advanced Non Small Cell Lung Cancer

EP05.01-006. Population Kinetic Assessment of Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

EP05.01-007. CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)

EP05.01-008. The Scottish Inflammatory Prognostic Score predicts survival in non-small cell lung cancer treated with chemoradiotherapy

EP05.01-009. A Clinical Outcome Comparison of IMRT and VMAT in Stage II and III NSCLC Irradiated with Radical Intent

EP05.01-010. External Validation of Two Prediction Models for Severe Radiation-induced Lymphopenia during Concurrent Chemoradiotherapy for Lung Cancer

EP05.01-011. Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience

EP05.01-012. Avoiding Cardiac Toxicity in Lung Cancer Radiotherapy (ACcoLade) Trial - Initial Results

EP05.01-013. Increased C-reactive Protein after Chemoradiotherapy and Immunotherapy in Locally Advanced Non-small Lung Cancer Indicates Worse Survival

EP05.01-014. Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer

EP05.01-015. Validate Radiomics Features and XGBoost Model in Radiation Pneumonitis (RP) Prediction in Patients with Primary Lung Cancer: A MultiCenter Study

EP05.01-016. Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer

EP05.01-017. Exploring the Benefits of Adaptive Radiotherapy in NSCLC-patients

EP05.01-018. Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia

EP05.01-019. 4D CT Ventilation Image-Guided Lung Functional Avoidance Radiotherapy: A Single-Arm Prospective Pilot Clinical Trial

EP05.01-020. Unanticipated Radiation Re-planning for Stage III Non-small Cell Lung Cancer

EP05.01-021. Radiation Dose to Cardiac Substructures and the Incidence of Cardiac Events in Patients with Stage III NSCLC Receiving CCRT

EP05.01-022. Evaluation of the Management of Stage III NSCLC at Mohamed IV Center for Cancer Treatment Casablanca

EP05.01-023. Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial

EP05.01-024. Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study

EP05.01-025. Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer

EP05.01-026. Carboplatin Dose Calculations for Patients with Lung Cancer: Significant Dose Differences Found Depending on Dosing Equation

EP05.01-027. Uncertain Resection of pN2 NSCLC Patients-survival Analysis of Postoperative Radiotherapy and Driver Gene Mutations

EP05.01-028. Thoracic Radiotherapy of Baseline Severe Pulmonary Dysfunction NSCLC Patients and Predictive Analysis for Acute Radiation Pneumonitis

EP05.01-029. Association between DNA Repair Gene Pathway SNPs and Tumour Response in NSCLC Patients Receiving Radiotherapy: A Meta-Analysis

EP05.01-030. CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315

EP05.01-031. Lysimachia Capillipes Capilliposide C Enhances the Radiosensitivity of Lung Cancer by Promoting ERRFI1 via Inhibiting Phosphorylation of STAT3

EP05.01-032. The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC

EP05.01-033. Stimulation CT-Based Radiomics Predict Radiation Pneumonitis after Chemoradiotherapy in Locally Advanced NSCLC

EP05.01-036. Role of Nanoparticle Polymeric Micellar Paclitaxel in Reducing Toxicity and Enhancing Efficacy in Non-small Cell Lung Cancer

EP05.02-001. Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort

EP05.02-002. Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

EP05.02-003. Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting

EP05.02-004. Could Fifty Percent Tumor Viability Be a Good Prognostic Factor?

EP05.02-005. Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?

EP05.02-007. Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery

EP05.02-008. Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer

EP05.02-009. Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)

EP05.02-010. Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemoimmunotherapy in Patients with Stage III Non-small Cell Lung Cancer

EP05.02-011. Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

EP05.02-012. Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC) Patients

EP05.02-013. Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC

EP05.02-014. Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-Arm, Phase 2 Trial (Renaissance Study)

EP05.02-015. Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-small-Cell Lung Cancer: Optimizing Outcomes throughout the Trajectory of Care

EP05.02-016. Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation

EP05.02-017. Prognostic Factors Following Induction Therapy for N2 Lung Cancer

EP05.02-019. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network

EP05.02-020. IL-9Stimulates Anti-tumor Immune Response and Facilitates Checkpoint Blockade in Lung Cancer

EP05.02-021. An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC

EP05.02-022. Thoracic Radiotherapy May Increase the Risk of Treatment-induced Pneumonitis after Immune Checkpoint Inhibitors: A Meta-Analysis

EP05.03-001. Impact of Neoadjuvant Chemo/radiotherapy Followed by Surgical Resection on T4N0-1 Non-Small Cell Lung Cancer

EP05.03-002. Pulmonary Artery Reconstruction for Lung Cancer With N1 Vessel Infiltration: Is It Justified?

EP05.03-003. Superior Sulcus (Pancoast) Tumors: A 11-Year Single-Centre Experience

EP05.03-004. Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 Non-small Cell Lung Cancer

EP05.03-006. Real-World Treatment Pathways In Stage III Non-Small Cell Lung Cancer in Portugal (PICTuRE): An Interim Analysis Of Surgical Patients

EP05.03-007. Comparison of Surgical Methods in Patients Receiving Neoadjuvant Treatment; Thoracoscopy vs. thoracotomy

EP05.03-008. Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results

EP05.03-009. Prognostic Impact of Tumor Volume Doubling Time for Resected Squamous Cell Carcinoma of the Lung

EP05.03-010. Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: A Systematic Review and Meta-analysis

EP05.03-011. Bilateral Orthotopic Lung Transplantation for a Patient with Advanced Invasive Mucinous Adenocarcinoma

EP05.03-012. Deep Learning-based Classifier to Predict Intensified Locoregional Approach Need in Stage III Non-Small Cell Lung Cancer

EP06.01-001. The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review

EP06.01-002. Cancer Care in a Time of COVID: Lung Cancer Patient's Experience of Telehealth and Connectedness

EP06.01-003. Impact of COVID-19 on Lung Cancer Patients; The Patients' Perspective

EP06.01-004. Lung Cancer Resection During the Covid-19 Pandemic: A Single Centre Study

EP06.01-005. COVID-19 and Post-COVID Outcomes in Lung Cancer Patients: Experience from an Indian Cancer Center

EP06.01-006. Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis

EP06.01-007. Fate of Pneumonectomy Patients During Covid-19 Pandemic

EP06.01-008. COVID-Protected Pathways for Image Guided Lunc Cancer Intervention During the COVID-19 Pandemic: A Cohort Study

EP06.01-009. Maintaining Thoracic Services During COVID-19 - A Single Centre Experience

EP06.01-010. Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco

EP06.01-011. COVID-19 Impact in Thoracic Surgery: a Comparison Between Public and Private Care in a Single-Center Facility

EP06.01-012. Impact of COVID-19 on the Stage of Lung Cancer Diagnosis at the Mohamed VI Center for Cancer Treatment in Morocco

EP06.01-013. Differences of Oncology Treatment for Lung Cancer Patients in Pandemic COVID-19 Year: Our Clinical Experience

EP06.01-014. Lung Resections After COVID: Short-term Outcomes

EP06.01-015. Will Virtual Care Stand the Test of Time; One Site's Perspective on the Continuity of Virtual Care Post-Pandemic

EP06.01-016. Nationwide Activity of Lung Cancer Surgery Before and During the COVID-19 Pandemic

EP06.01-017. Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours

EP07.01-001. Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma

EP07.01-002. Surgery in Stage I-III Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER)- Medicare Analysis 1995-2015

EP07.01-003. Metadata-Oriented Data Engineering Approach for Integration of Medical Data: A Pilot Study

EP07.01-004. Long Survivor Epithelioid Pleural Mesotheliomas Are Characterized by Tertiary Lymphoid Structures: An Update to the MATCH Study

EP07.01-005. Second Primary Cancers in a Population-Based Mesothelioma Registry

EP07.01-006. Clinicopathologic Determinants of Survival in Thoracic NUT Carcinoma (TNUT): Analysis of a Pooled Database

EP07.01-007. Is Extended Resection for Tracheo Bronchial Adenoid Cystic Carcinoma Warranted?

EP07.01-008. Perturbation of Warburg Effect by Dichloroacetate and Niclosamide in Malignant Pleural Mesothelioma in Vitro and in Vivo

EP07.01-009. Solitary Fibrous Tumors of the Pleura, Clinical and Surgical Dilemma. Single-Center Experience

EP07.01-010. Results of Multimodal Treatment in Patients with Malignant Pleural Mesothelioma Undergoing Pleurectomy/Decortication

EP07.01-011. Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma

EP07.01-012. Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma

EP07.01-013. Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma

EP07.01-014. Mesothelioma-Associated Fibroblasts Enhance Mesothelioma Aggressiveness and Modulate Drug Response

EP07.01-015. Multimodality Imaging for Characterization, Classification, and Staging of Malignant Pleural Mesothelioma, Focusing on MR Imaging

EP07.01-016. Role of Neoadjuvant Chemotherapy in Thymic Tumors

EP07.01-017. Malignant Fibrous Solitary Tumour of the Pleura Is Not All the Same: Evaluation of Risk Stratification Models in a Large Single Centre Series

EP07.01-018. Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)

EP07.01-019. Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma

EP07.01-020. Pulmonary MALT Lymphoma: Detailed CT Findings

EP07.01-021. Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy

EP07.01-022. Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)

EP07.01-023. Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)

EP07.01-024. Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma

EP07.01-025. Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study

EP07.01-026. Primary Pulmonary Ewing'S Sarcoma: Post Hoc Analysis From Two International Multicenter Prospective Randomized Trials

EP07.02-001. Evaluation of FGF18 as a Contributing Factor in Malignant Pleural Mesothelioma Growth and Its Role as a Potential Biomarker

EP07.02-002. Investigating the Role of MicroRNAs in Cell Growth and Cisplatin-Sensitivity of Malignant Pleural Mesothelioma

EP07.02-003. Characterization of the Extracellular Vesicle-Derived Transcriptome in Malignant Pleural Mesothelioma

EP07.02-004. Endogenous Retrovirus Expression and Type I Interferon Signaling in Human Mesothelioma

EP07.03-001. Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma

EP07.03-002. Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience

EP07.03-003. First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial

EP07.03-004. Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma

EP07.03-005. MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images

EP07.03-006. Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data

EP07.03-007. Clinicopathological Analyses for Predicting Recurrence After Complete Resection of Thymoma

EP08.01-001. Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer

EP08.01-002. Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy

EP08.01-003. Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study

EP08.01-004. Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab

EP08.01-005. A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL

EP08.01-006. Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy

EP08.01-007. Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy

EP08.01-008. Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer

EP08.01-009. TRBV Haplotype Profile Was Related to Immune-Induced Adverse Events in Chinese Patients With Advanced NSCLC

EP08.01-010. Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors

EP08.01-011. Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients

EP08.01-012. First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience

EP08.01-013. Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade

EP08.01-014. Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303

EP08.01-015. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumors

EP08.01-016. A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy

EP08.01-017. Evaluation of Blood Tumor Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer

EP08.01-018. Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression

EP08.01-019. Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer

EP08.01-020. Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)

EP08.01-021. Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy

EP08.01-022. Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events

EP08.01-023. Factors Associated with Survival and Refusal of Physician Recommended Immunotherapy in Metastatic Non Small Cell Lung Cancer

EP08.01-024. Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey

EP08.01-025. PD-L1 Tumor Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC

EP08.01-026. Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients

EP08.01-027. Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON

EP08.01-028. Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer

EP08.01-029. NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases

EP08.01-030. Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

EP08.01-031. Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response

EP08.01-032. Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study

EP08.01-033. ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC

EP08.01-034. Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy

EP08.01-035. Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC

EP08.01-036. Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner

EP08.01-037. Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy

EP08.01-038. Clinical Predictors of Treatment Efficacy in Patients with Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors

EP08.01-039. Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors

EP08.01-040. Peripheral Blood Cells as Predictors for Efficacy of Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer

EP08.01-041. Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

EP08.01-042. NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC

EP08.01-043. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)

EP08.01-044. A Phase 2 Multi-Cohort Study of Tiragolumab, Atezolizumab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer

EP08.01-045. The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival

EP08.01-046. Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution

EP08.01-047. Chemo-immunotherapy is Associated With Better Survival Than Chemotherapy Alone In Stage IV Non-small Cell Lung Cancer

EP08.01-048. Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort

EP08.01-049. Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy

EP08.01-050. Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)

EP08.01-051. Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy

EP08.01-052. Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study

EP08.01-053. PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs

EP08.01-054. ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer

EP08.01-055. Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer

EP08.01-056. Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting

EP08.01-057. Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS

EP08.01-058. Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer

EP08.01-059. Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer

EP08.01-060. Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data

EP08.01-061. A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor

EP08.01-062. Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy

EP08.01-063. Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%

EP08.01-064. Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC

EP08.01-065. Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer

EP08.01-066. Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?

EP08.01-067. Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC

EP08.01-068. Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?

EP08.01-069. A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs

EP08.01-070. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

EP08.01-071. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

EP08.01-072. Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy

EP08.01-073. AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

EP08.01-074. 'Long Responders' Compared to 'Non-Responders' to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer

EP08.01-075. Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression

EP08.01-076. KEYNOTE B36: A Pilot Study of First-line Tumor Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer

EP08.01-077. Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC

EP08.01-078. Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors

EP08.01-081. A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab

EP08.01-082. Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study

EP08.01-083. Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden

EP08.01-084. Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients

EP08.01-085. Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer

EP08.01-086. Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer

EP08.01-087. First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices

EP08.01-088. Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C

EP08.01-089. Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer

EP08.01-090. Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

EP08.01-091. Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront

EP08.01-093. ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer

EP08.01-094. A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)

EP08.01-095. Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study

EP08.01-096. Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor Combined with Chemotherapy for Non-small Cell Lung Cancer

EP08.01-097. Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy

EP08.01-098. Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation

EP08.01-099. Activity of aPD1-MSLN-CART Cells against Metastatic Lung Cancer in a Phase 1 Trial

EP08.01-100. Unlocking Primary Resistance to Checkpoint Inhibitors in Non-small Cell Lung Cancer by Metagenomic and Metabolomic

EP08.01-101. Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC

EP08.01-102. Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy

EP08.01-103. Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer

EP08.01-104. Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy

EP08.01-105. Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations

EP08.01-106. PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer

EP08.01-107. The Increase of Blood Intratumor Heterogeneity Is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC

EP08.01-108. Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC - A Propensity-Score Matched Case-Control Study

EP08.01-109. TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

EP08.01-110. Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC

EP08.02-001. Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

EP08.02-002. Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia

EP08.02-003. Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis

EP08.02-004. Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY

EP08.02-005. A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC

EP08.02-006. Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients

EP08.02-007. Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners

EP08.02-008. Tumor Invasiveness and Clinical Outcomes between Metastatic ROS-1 and ALK Positive NSCLC

EP08.02-009. Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second-Generation ALK-TKIs

EP08.02-010. Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China

EP08.02-011. Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC

EP08.02-012. Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea

EP08.02-013. Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC

EP08.02-014. Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort

EP08.02-015. The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center

EP08.02-016. Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

EP08.02-017. Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data

EP08.02-018. Phase 1/2 Study of BLU-451, a Small Molecule Inhibitor of EGFR, in EGFR Exon 20 Insertion-Mutant Incurable Advanced Cancers

EP08.02-019. Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

EP08.02-020. Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation

EP08.02-021. A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases

EP08.02-022. Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen

EP08.02-023. Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib.

EP08.02-024. Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis

EP08.02-025. Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

EP08.02-026. Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.

EP08.02-027. T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC

EP08.02-028. Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study

EP08.02-029. Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

EP08.02-030. Tusamitamab Ravtansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

EP08.02-031. NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC

EP08.02-032. High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid

EP08.02-033. Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study

EP08.02-034. OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L

EP08.02-035. Clinical Utility of Liquid Biopsy After Progression to First and Second-Generation TKIs in Advanced EGFR Mutant NSCLC Patients

EP08.02-036. Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer

EP08.02-037. Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib

EP08.02-038. Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

EP08.02-039. An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib

EP08.02-040. Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event

EP08.02-041. NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study

EP08.02-042. EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC

EP08.02-043. The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers

EP08.02-044. Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC

EP08.02-045. Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer

EP08.02-046. Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)

EP08.02-047. The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs

EP08.02-048. Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

EP08.02-049. A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations

EP08.02-050. A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis

EP08.02-051. High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC

EP08.02-053. Non-small Cell Lung Cancer withMETExon14 Skipping Mutation: Literature Review of Real-World Evidence Data

EP08.02-054. Efficacy and Safety of TKI Dose Reduction - Can Less Mean More?

EP08.02-055. Targeting Lung Adenocarcinoma Cells with a Novel Disulfide Reductase Inhibitor

EP08.02-056. Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors

EP08.02-057. Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance

EP08.02-058. A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience

EP08.02-059. EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis

EP08.02-060. How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry

EP08.02-061. Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?

EP08.02-062. Evaluation of In Silico Tools to Determine Potential Actionability of Missense Variants with Experimental Therapies for NSCLC

EP08.02-063. SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC

EP08.02-064. ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

EP08.02-065. Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations

EP08.02-066. Real-World Data on the Side Effects of Alectinib, Brigatinib and Lorlatinib

EP08.02-067. Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

EP08.02-068. ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)

EP08.02-069. A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases

EP08.02-070. High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer

EP08.02-071. Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort

EP08.02-072. The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs

EP08.02-074. Impact of Germline BRCA1/2 Alterations on EGFR Mutant Advanced Non-small Cell Lung Cancer Outcomes

EP08.02-075. Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion

EP08.02-076. Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab

EP08.02-077. Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes

EP08.02-078. Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)

EP08.02-079. The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance

EP08.02-080. EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting

EP08.02-081. Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC

EP08.02-082. Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study

EP08.02-083. Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients

EP08.02-084. Evaluation of Tumor Heterogeneity (TH) as a Prognostic Biomarker in Osimertinib treated Non-Small Cell Lung Cancer Patients

EP08.02-085. In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI

EP08.02-086. Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma

EP08.02-087. A 28-Years Old Pregnant Woman Diagnosed as ALK-Rearrangement Lung Adenocarcinoma With Multiple Brain Metastasis - Case Report

EP08.02-088. Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients

EP08.02-089. Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer

EP08.02-090. Sotorasib Drug-Drug Interactions: Essential Guidance Requested by Physicians Worldwide

EP08.02-091. Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA

EP08.02-092. Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib

EP08.02-093. Loss of Tumor Endothelial QKI Expression Results in Pronounced Reductions in Metastasis and Remodeling of the Tumor Microenvironment

EP08.02-094. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial

EP08.02-095. Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib

EP08.02-096. Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis

EP08.02-097. Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina

EP08.02-098. Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC

EP08.02-099. Liquid Biopsies as a Tool for Monitoring Patients with Metastatic ALK-positive NSCLC

EP08.02-100. Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression

EP08.02-101. Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study

EP08.02-102. Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer

EP08.02-103. Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience

EP08.02-104. Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World

EP08.02-105. KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study

EP08.02-106. KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

EP08.02-107. Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer

EP08.02-108. Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

EP08.02-109. A Drug-Drug Interaction Study of Mobocertinib and Midazolam in Patients With Advanced Non-Small Cell Lung Cancer

EP08.02-110. Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy

EP08.02-111. RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial

EP08.02-112. Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province

EP08.02-113. Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

EP08.02-114. Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

EP08.02-115. A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

EP08.02-116. Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors

EP08.02-117. Online CME Improves Clinicians' Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations

EP08.02-118. TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors

EP08.02-119. RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer

EP08.02-120. MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions

EP08.02-121. The Landscape of Anti-neoplastic Drugs for Malignant Pleural Effusion in Non-small Cell Lung Cancer: A Systematic Review of Clinical Trials

EP08.02-122. Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)

EP08.02-123. First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence

EP08.02-124. Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC

EP08.02-125. Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer

EP08.02-126. The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

EP08.02-127. Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

EP08.02-128. Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial

EP08.02-129. Closing the Gaps with Blood-Based Next Generation Sequencing

EP08.02-130. Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment

EP08.02-131. Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program

EP08.02-132. Fatal Interstitial lung disease induced by Osimertinib: a case report

EP08.02-133. Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report

EP08.02-134. Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer

EP08.02-135. Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)

EP08.02-136. Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer

EP08.02-137. Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment

EP08.02-138. SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib

EP08.02-139. A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

EP08.02-140. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

EP08.02-141. Our' EGFR population - experience in a secondary center

EP08.02-142. Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC

EP08.02-143. Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.

EP08.02-144. The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer

EP08.02-145. An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World

EP08.02-146. Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation

EP08.02-147. Clinical Outcomes in Patients with or without Cell Cycle Gene Alterations in EGFR mutated Non-Small Cell Lung Cancer

EP08.02-148. Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer

EP08.02-149. Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab

EP08.02-150. Molecular Heterogeneity of Compound Epidermal Growth Factor Receptor (EGFR) Mutations in Lung Adenocarcinoma (LAC)

EP08.02-151. A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer

EP08.02-152. Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis

EP08.02-153. The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC

EP08.02-154. Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial

EP08.02-155. The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients

EP08.02-156. Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US

EP08.02-157. Acquired EGFR Exon 19 Deletion Is a Resistance Mechanism to BRAF/MRK Inhibition in BRAF V600Emutant NSCLC

EP08.02-158. Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC

EP08.02-159. Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study

EP08.02-160. A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy

EP08.02-161. An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer

EP08.02-162. Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

EP08.02-163. Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer

EP08.02-164. The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand

EP08.02-166. Brain Metastases in Patients with ALKrearranged or ROS1-fusion Non-small-Cell Lung Cancers in China

EP08.02-167. Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters

EP08.02-168. Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute

EP08.02-169. Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation

EP08.02-171. PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EP08.02-172. Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis

EP08.02-173. Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings

EP08.02-174. RET Fusions as Primary Oncogenic Drivers and Secondary Acquired Resistance to EGFR TKI in a Large Cohort of Non-Small-Cell Lung Cancers

EP08.03-001. A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases

EP08.03-002. Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India

EP08.03-003. Surgery for Primary Tumor is Associated with Prolonged Overall Survival in Patients with Oligometastatic NSCLC

EP08.03-004. Outcomes of Oligometastatic Non-Small Cell Lung Cancer Patients Undergoing Surgical Resection: A Single Center Experience

EP08.03-005. HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours

EP08.03-006. Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis

EP08.03-007. Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report

EP08.03-008. Whether Immunotherapy Should Be Maintained or Not After Acquired Resistance in Advanced NSCLC

EP08.04-001. Weekly versus 3-Weekly Regimens of Carboplatin and Paclitaxel in Metastatic NSCLC: A Real-World Data

EP08.04-002. Australian Vinorelbine Use in Advanced Lung cancer (The AVAL Study)

EP08.04-003. A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

EP08.04-004. Impact of Comorbidity Scores on Overall Survival in Advanced Non-Small Cell Lung Cancer Patients -A Real-World Experience from Eastern India

EP08.04-005. Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion

EP08.04-006. Risk Factors of Chemotherapy-Induced Severe Neutropenia in Elderly Lung Cancer: Data From a Regional Hospital in Thailand

EP08.05-001. Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation

EP08.05-002. Sequencing of T cell Receptor Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis

EP08.05-003. Evaluation of Dose Changes in Different Periods after 125I Seed Implantation in Lung Cancer

EP08.05-004. The Optimal Intervention Timing of Hypofractionated Stereotactic Radiotherapy for EGFR Mutated NSCLC Patients With Limited Brain Metastases

EP09.01-001. International Collaboration for Thoracic Oncology Education

EP09.01-002. Patient with Immune-associated Dermatomyositis Caused byAdvanced NSCLC Treated with ICIs

EP10.01-001. Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity

EP10.01-002. The Effect of Group Rehabilitation Training in the Ward on the Psychological Status and Quality of Life of Lung Cancer Patients

EP10.01-003. Non-Small Cell Lung Cancer Treatment Preferences Among EGFR Mutation Patients and Physicians in Japan

EP10.01-004. Perspectives of Patients with Metastatic Lung Cancer on Symptom Screening and Patient-Reported Symptom Trajectory Data

EP10.01-005. Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs

EP10.01-006. Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients

EP10.01-007. Real World Data Comparing Lung Cancer Side-Effects Between Past/Current Smokers And Never Smokers

EP10.01-008. Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation

EP10.01-009. The Impact of the COVID-19 Pandemic on Palliative Care for Cancer: A Preliminary Cross-Country Survey of Clinical Oncologists

EP10.01-010. Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)

EP10.01-011. Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab

EP10.01-012. Geriatric Assessment in Patients Undergoing Lung Cancer Surgery and Their Family Caregivers

EP10.01-013. Erector Spinae Plane Block for Post-thoracotomy Analgesia; Comparison with Intercostal Block; Preliminary Results

EP10.01-014. A Multidisciplinary Team to Manage Patients with Lung Cancer and Opioid Use Disorder

EP10.01-015. The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.

EP10.01-016. Cachexia's Impact on Immunotherapy Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review

EP10.01-018. Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial

EP10.01-019. Rowing Against Cancer: From a Support Project to a Research Program. Perspectives and Challenges of Rowing in Metastatic Lung Cancer Patients

EP10.01-020. Nutritionassessment for With Common Cancer Patients in a Cancer Hospital of China

EP11.01-002. Malignant Pleural Effusion Cell Blocks Are Reliable Resources for PD-L1 Analysis in Advanced Lung Adenocarcinomas

EP11.01-003. Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation

EP11.01-004. An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer

EP11.01-005. Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients

EP11.01-006. Setting Up an Ultra-Fast Next-Generation Sequencing Approach as a Reflex Testing at Diagnosis in Non-squamous Non-small Cell Lung Cancer

EP11.01-007. Tracking ROS1 Fusions in NSCLC - Mirage or Truth When Screening the Desert

EP11.01-008. Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System

EP11.01-010. A Prospective Validation Study of Lung Cancer Gene Panel Testing Using Cytological Specimens

EP11.01-011. Clinical Application of Liquid Biopsy for Assessing Early EGFR Mutation Detection in Non-Small Cell Lung Carcinoma

EP11.01-012. Genomic Landscape of Liquid Biopsy in Advanced Lung Cancer Patients, an Indian Experience

EP11.01-013. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma

EP11.01-014. Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS

EP11.02-001. Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports

EP11.02-002. A Comparative Study of PD-L1 Scoring: Humans versus AI

EP11.03-001. Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index

EP11.03-002. Prognostic Significance of YAP1 and Its Association with Neuroendocrine Markers in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC)

EP11.03-003. Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases

EP11.03-004. Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma

EP11.04-001. Cytokeratin 5-Positive Pulmonary Adenocarcinoma: A Study with Resected Specimens

EP11.04-002. The Histopathological Reasons for Better Survival of Patients with Lepidic Pattern Dominant Adenocarcinoma

EP12.01-001. What Do Patients Want - a European Study Into ALK-Positive Patients Perspectives

EP13.01-001. The Burden of Incidental Extra-thoracic Positron Emission Tomography-CT (PET-CT) Findings in Thoracic Malignancies

EP13.01-002. Radiomic Signature on CT Images: A Noninvasive Biomarker for Pretreatment Discrimination of EGFR Mutations in NSCLC Patients

EP13.01-003. Diagnostic Yield of Radial Probe Endobronchial Ultrasonography without Fluoroscopic guidance in Peripheral Pulmonary Lesions

EP13.01-004. Accuracy of Clinical Stage in Resectable Non-small Cell Lung Cancer (NSCLC)

EP13.01-005. Role of Artificial Intelligence on Chest Radiographs for Detecting Resectable Early Lung Cancer

EP13.01-006. Safety of Image Guided Research Biopsies in Patients with Thoracic Malignancies

EP13.01-007. Differentiation between heterogeneous GGNs and part solid nodules using histogram on thin-section CT

EP13.01-008. Needle Aspiration versus Forceps Biopsy Using Electromagnetic Navigation Bronchoscopy: CONFIDENT-ENB Trial Design

EP13.01-009. A Modified T Categorization for Pathological Stage I Lung Adenocarcinoma with Lepidic Component in Chinese Population

EP13.01-010. Effect of Perioperative Respiratory Muscle Training with Gamification for Lung Cancer

EP13.01-011. Combining Automated Malignancy Risk Estimation with Lung Nodule Detection May Reduce Physician Effort and Increase Diagnostic Accuracy

EP13.01-012. Exploring Factors Affecting Variability in Lung Cancer Outcomes Across Southeastern Ontario, Canada

EP13.01-013. Determination of the Timing of Bevacizumab Administration in Osimertinib and Bevacizumab Combination Therapy

EP13.01-014. Evaluation of Malignancy and Survival in Patients Operated With a Preliminary Diagnosis of Interstitial Lung Disease

EP13.01-015. Correlation Between CT Signs and Ki67 Expression in Non-small Cell Lung Cancer

EP13.01-016. Are Follow-up Tests Useful in NSCLC? Experience of a Tertiary Hospital

EP13.01-017. Assessing Variance Between Radiology versus Multidisciplinary Clinic Recommendations in the Pulmonary Nodule and Lung Screening Clinic

EP14.01-001. SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report

EP14.01-002. Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer

EP14.01-003. Parotid Metastases from Primary Lung Cancer: Case Series and Systematic Review on the Clinical Features

EP14.01-005. Weekly Sequential ACOCEV Chemotherapy (ADR, CTX, CBDCA, VP16, VCR) for Elderly - Poor PS SCLC Patients: An Observational Study

EP14.01-006. CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019

EP14.01-007. Next-Generation Sequencing to Dynamically Detect Mechanisms of Resistance to ALK Inhibitors in ALK-positive SCLC Patient: A Case Report

EP14.01-008. Checkpoint Inhibitors Prevent New Onset of Brain Metastases in Relapsed Extensive Disease Small-Cell Lung Cancer

EP14.01-009. A Comparative Study of Histological Predictors of Outcome in Patients with Lung Typical and Atypical Carcinoids

EP14.01-010. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer

EP14.01-011. Carcinoid Tumor of the Lung with Osteomimicry. Case Report

EP14.01-012. A Case Report of Lung Large Cell Neuroendocrine Carcinoma with Carcinoid Morphology

EP14.01-013. First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung, a Retrospective Study

EP14.01-014. Risk Factors for Brain Metastasis in Patients with Small Cell Lung Cancer: A Systematic Review and Meta-analysis

EP14.01-015. IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC

EP14.01-016. Anlotinib Plus Toripalimab as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer: a Single-Arm Phase II Study

EP14.01-018. Small Cell Lung Carcinoma in Morocco

EP14.01-019. Identifying Circulating DNA Methylation Patterns in Small Cell Lung Cancer Patients

EP14.01-020. Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Therapy in Treatment-Naïve Extensive Stage Small Cell Lung Cancer

EP14.01-021. Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed within Six Months: a Single-Arm Phase II Study

EP14.01-022. Immune Thrombocytopenia in a Patient with Large Cell Neuroendocrine Carcinoma Under Dual Immune Checkpoint Inhibition

EP14.01-023. A Randomized Phase II Study of Irinotecan Plus Cisplatin With or Without Simvastatin in Ever-Smoking Small Cell Lung Cancer

EP14.01-024. Transformation of SCLC to Lung Squamous Cell Carcinoma after First-Line Chemotherapy and Response to Sintilimab: A Case Report

EP14.01-025. Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients

EP14.02-001. Could the Oxidative Stress Be Used as a Marker for Neuroendocrine Lung Tumors?

EP14.02-002. Cisplatin in Combination with Entinostat exerts Synergistic Antineoplastic Activity in Small Cell Lung Cancer

EP14.02-003. Clinical Significance of MYC Family Members in Surgically Resected Limited-Stage Small Cell Lung Cancer: A Multicenter Study

EP14.02-004. Barasertib Inhibits the Growth of SCLC Cell Lines and Transformed SCLC Patient Derived Model In Vitro and In Viv

EP14.02-005. Therapeutic Targeting Mevalonate-Geranylgeranyl Diphosphate Pathway with Statins Overcomes Chemotherapy-resistance in SCLC

EP14.02-006. Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer

EP14.03-001. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive Stage Small Cell Lung Cancer

EP14.03-002. Low-Dose Radiotherapy Plus Sugemalimab in Second-Line Treatment for Advanced-Stage Small-Cell Lung Cancer: Initial Results of a Phase I Study

EP14.03-003. Phase I Study of Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

EP14.03-004. Neuro-cognitive Effect of HS-PCI in LS-SCLC

EP14.03-005. Role of Radiotherapy Fraction in Limited-Stage SCLC: a Meta-Analysis of 8585 Reconstructed Individual Patient Data

EP14.04-001. Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE)

EP14.04-002. The Impact of Response on Survival in Extensive-Stage Small-Cell Lung Cancer in the CASPIAN Study

EP14.05-001. Chemoimmunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer and ECOG Performance Status of 2 or 3

EP14.05-002. Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer

EP14.05-003. Recent Stage Shifts and Changes in the Treatment of Stage I Small Cell Lung Cancer in the United States

EP14.05-004. Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial

EP14.05-005. Survival of Small Cell Lung Cancer in Relation to Chemotherapy Dose Intensity

EP14.05-006. The Impact of Adjuvant Chemotherapy on Survival of Stage I Lung Large Cell Neuroendocrine Carcinoma: A Meta-Analysis of Comparative Studies

EP14.05-007. A Study of the Best Reduction in Target Lesion Size and Treatment Duration in the Durvalumab plus Platinum-Etoposide Regimen for ES-SCLC

EP14.05-009. LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)

EP14.05-010. Real-World Eligibility for Clinical Trials in Extensive Stage Small Cell Lung Cancer Patients

EP14.05-011. Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer

EP14.05-012. Comparing Costs for Medicare FFS Patients Treated with Etoposide or Irinotecan for Extensive Stage Small Cell Lung Cancer

EP14.05-013. Real-World Resource Use and Costs by Stage and Platinum Sensitivity among Medicare Patients with Small Cell Lung Cancer

EP14.05-014. Trends in Population Survival Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

EP14.05-015. Quantifying Recent Trends in Real-World Treatment Patterns Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

EP14.05-016. Patterns of Care for Small Cell Lung Cancer in Victoria Australia. A Prospective Population-Based Observational Study

EP14.05-017. Real World Eligibility of Immune Checkpoint Inhibitors with Platinum-Doublet in Extensive Stage Small Cell Lung Cancer

EP14.05-018. Major Lung Resection for Carcinoid Tumor; Does It Affect Quality of Life?

EP14.05-019. Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021

EP14.05-020. Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)

EP14.05-021. Promising Long-Term Survival after Surgical Resection of Early Stage Small Cell Lung Cancer in a Modern Single-Center Cohort

EP14.05-022. The Drug Induced Interstitial Lung Disease in Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer

EP14.05-023. Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States

EP15.01-001. Ask, Advise, Help (AAH) Smoking Cessation Brief Advice Delivery in Patients with Diagnosed Lung Cancer: A Retrospective Audit

EP15.01-002. Lowering Rates of Smoking after Cancer Diagnosis: Use Social Networks

EP16.01-001. Transforming Growth Factor-inhibits Interferon-mediated Immune Resistance in Lung Cancer

EP16.01-002. T Cell Receptor Diversity among Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab Alone or in Combination with Chemotherapy

EP16.01-003. The Dynamic Immune Signature of Patients with Advanced Non-small Cell Lung Cancer in Prediction of Infection After Receiving Immunotherapy

EP16.01-004. Pleural Mesotheliomas Related with Geographical Asbestos Exposure Show Higher PD-L1 Expression

EP16.01-005. Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma

EP16.01-006. CD47 Inhibition Impairs the Growth of Orthotopic, Immune Competent Lung Tumour Models

EP16.01-007. Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy

EP16.01-008. The Effect of Cytochrome P450 Family 4 Subfamily B Member 1 (CYP4B1) on Lung Adenocarcinoma (LUAD) Immune Microenvironment

EP16.01-010. A Machine-Learning Based Survival Prediction for Lung Adenocarcinma by Analyzing Infiltrated Lymphocytes Profiles with CIBERSORT

EP16.01-011. PD-L1 Expression on Cytological Imprints and Circulating Tumor Cells versus Standardized Immunohistochemistry in NSCLC

EP16.01-012. Immunophenotyping of Lung Adenocarcinoma in situ Based on CD8-positive T Cell Infiltration

EP16.01-013. The Diagnostic Accuracy of Tumor Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis

EP16.01-014. Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy

EP16.01-015. Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients

EP16.01-016. Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages

EP16.01-017. T-cell Repertoire Heterogeneity and Homogeneity in Synonymous Multiple Primary Lung Cancers

EP16.01-018. SAKK 16/14 -Peripheral Immune Cell Populations Inresponse to Neoadjuvant Durvalumab in Patients with Stage IIIA(N2) NSCLC

EP16.01-019. The Role of the Pregnancy Associated Protein Glycodelin and Its Influence on the Immune System in Non-small-Cell Lung Cancer

EP16.01-020. Predictive Effect of Spatial Protein Signature in Advanced NSCLC Receiving Immunotherapy with a Bispecific Antibody

EP16.01-021. Less Immune Cell Infiltration and Worse Prognosis for NSCLC Patients with XPO1 Copy Number Alterations

EP16.01-022. A Signature of B Cells-Related Gene Pairs Predicts Oncologic Outcomes and Response to Immunotherapy in NSCLC Patients

EP16.01-024. Differential Efficacy of Combined GITR Co-stimulation with PD-1 Blockade in Preclinical Non-small Cell Lung Cancer Models

EP16.01-025. Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer

EP16.01-027. MIF ImprovesImmune Microenvironmentof Lewis Lung Cancer Brain Metastases after Radiotherapy ViaReducing M2 Macrophages

EP16.01-028. Immunomodulatory Effects of Cryoablation Combined With Immune Checkpoint Inhibitors in a Murine Lung Cancer Model

EP16.01-029. Inter-tumor Heterogeneity of PD-L1 Expression in Non-small Cell Lung Cancer

EP16.01-030. Peripheral T-Cell Receptor Repertoire Profiling in Non-small Cell Lung Cancer Using an Amplicon-Based Sequencing Assay

EP16.01-031. Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)

EP16.01-032. Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients

EP16.01-033. Characterisation of T Cell Receptor Repertoire in Non-small Cell Lung Cancer Patients Treated With Immunotherapy

EP16.02-001. Integration of Primer Exchange Reaction and DNAzyme for Electrochemical Detection of PD-L1-Expressing Exosomes in Lung Cancer

EP16.02-002. Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study

EP16.02-003. Real World Experience and Feasibility of Tissue Informed CGP and ctDNA Testing in a Cohort of NSCLC Patients

EP16.02-004. Clinical Significance and Genomic Characteristics of CD56+ Circulating Tumor Cells in Small Cell Lung Carcinoma

EP16.02-005. Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing: WJOG13620L

EP16.02-006. Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer

EP16.02-007. Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies

EP16.02-008. Cerebrospinal Fluid as a Liquid Biopsy for Molecular Characterization of Brain Metastases in Patients With Non-small Cell Lung Cancer

EP16.02-009. Psychobiological Stress Responses to a Lung Cancer Diagnosis

EP16.02-010. Predictive Value of Serum Reactive Oxygen Species Modulator 1 for Surgically Resected Lung Adenocarcinoma

EP16.02-011. Liquid Biopsies in the Setting of Early-Stage Lung Cancer for the Detection of Actionable Mutations

EP16.02-012. cfDNA Analysis Implementation in Early Stage Lung Cancer

EP16.02-013. Retrospective Analysis of BRCA1/2 Alterations in Advanced NSCLC Using An Amplicon-based NGS Liquid Biopsy Assay

EP16.02-014. A Comparative Analysis of Gene Alteration Detected With NGS in Tumor Tissue and Peripheral Blood in Lung Cancer

EP16.02-015. Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC

EP16.02-017. Predictive Value of Peripheral Blood Immune Cell Profiling in EGFR-T790M Mutant Lung Adenocarcinoma

EP16.02-018. Liquid Biopsies First to Make Treatment Decisions in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC)

EP16.02-019. Metabolic Changes in Sputum and Exhaled Breath Condensate of Non-small Cell Lung Cancer Patients after Surgical Resection

EP16.02-020. Lung Cancer Cell Dynamics Significantly Depended on Blood Cell Circuit, Biochemical Factors, Hemostasis System, Cancer Characteristics

EP16.02-021. The Expression of CEACAMs and Serum CEA Levels as Biomarkers of Postoperative Cancer Recurrence in Non-small Cell Lung Cancer

EP16.02-022. Circulating Tumor DNA Minimal Residual Disease Assay Predicts Outcome in Lung Cancer Patients Who Had Curative Treatments

EP16.02-023. Extracellular Vesicles Long RNA Sequencing as Diagnostic Biomarkers for Lung Adenocarcinoma Patients with Tumor Size Smaller than 2cm

EP16.02-024. Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

EP16.02-025. SerumTumor Markers as a Surrogate forRadiographicAssessment of Non-Small Cell Lung Cancer

EP16.02-026. Dynamic Change of Indoleamine 2,3-dioxygenase Activity Predicts Survival in Radiotherapy- Received Unresectable Stage III NSCLC

EP16.02-027. Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients

EP16.02-028. Schwann Cell Exosomes Promote Lung Cancer Progression via miRNA-21-5P Cargo

EP16.02-029. Plasma-Based Next Generation Sequencing for Molecular Characterization of Lung Adenocarcinoma: A Multicentric Cohort From Argentina

EP16.03-001. High Frequency of KRAS Mutation, Uncommon EGFR Mutation and TMB-H in Xuanwei Female Patients With Lung Adenocarcinoma

EP16.03-002. Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)

EP16.03-003. Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)

EP16.03-004. Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition

EP16.03-005. Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists

EP16.03-006. Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients

EP16.03-007. Comprehensive Analysis of m6A-Related Gene Mutation Characteristics and Prognosis in Lung Adenocarcinoma

EP16.03-008. The Landscape of NFE2L2 Alteration in Chinese Lung Cancer Patients

EP16.03-009. Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping

EP16.03-010. Molecular and Clinical Characterization of Lung Adenocarcinoma With Respect to Patient Age at Diagnosis

EP16.03-011. The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity

EP16.03-012. Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC

EP16.03-013. Psychological Distress and Beta-2 Adrenergic Receptor Expression in Non-small Cell Lung Cancer Cells

EP16.03-014. Simultaneous Detection of FGFR Gene Aberrations in Squamous Non-small Cell Lung Cancer Using Targeted DNA- and RNA-based NGS

EP16.03-015. Centrosome Amplification Is a Prognostic Indicator and Potential Therapeutic Vulnerability in Non-small Cell Lung Cancer

EP16.03-016. Targetable Alterations in Non-Small Cell Lung Cancer According to Age and Sex

EP16.03-017. Spatial Heterogeneity of Tumor Microenvironment of Lung Adenocarcinoma Associated With Genomic Alterations

EP16.03-019. Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma

EP16.03-020. High Tumor Mutational Burden by Whole-Genome Sequencing in Resected NSCLC in Never Smokers is Associated with Worse Prognosis

EP16.03-021. Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)

EP16.03-022. Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Sampling Is Sufficient for Lung Cancer Molecular Profiling

EP16.03-023. KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients

EP16.03-024. Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A

EP16.03-025. Immunogenomics of Clinical Resistance to KRAS G12C Inhibition

EP16.03-026. Metastasis Sites and Genomic Alterations in Advanced Non Small Cell Lung Cancer: A Retrospective Study

EP16.03-027. Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC

EP16.03-028. Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway

EP16.03-029. SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed

EP16.03-031. Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants

EP16.03-032. Structure-Based Classification of Chinese Patients with Non-Canonical EGFR-Mutant Non-Small Cell Lung Cancer

EP16.03-033. Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups

EP16.03-034. Differential Prognostic Effect of EGFR Mutation According to Smoking Status and Pathologic Stage in Non-mucinous Lung Adenocarcinoma

EP16.03-035. Driver Mutations on Metastatic NSCLC - Experience in a Secondary Center

EP16.03-036. Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC

EP16.03-037. Poor Prognosis of Patients with EGFR Mutations Left behind by Selective Detection in NSCLC

EP16.03-038. Single-cell Analyses Reveal Tumor Microenvironment Differences between EGFR 19del and L858R mutations in Lung Adenocarcinoma

EP16.03-039. Characterizing SHPRH as a Novel Tumor Suppressor Gene in Lung Adenocarcinoma

EP16.03-040. Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base

EP16.03-041. Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers

EP16.03-042. BET Inhibitors Stimulate NK Cytotoxic Activity in NSCLC through Attenuation of YAP/TAZ and SMAD3 Transcriptional Programs

EP16.03-043. Comprehensive Genomic Profiling of Tumor Mutational Burden-high in Chinese Lung Cancer Patients

EP16.03-044. Genomic Evidence Depicting Clonal Evolution of Lung Adenosquamous Carcinoma

EP16.03-045. The Effect of Vascular Endothelial Growth Factor Gene Polymorphisms in the Clinical Outcome of Patients with Lung Cancer

EP16.03-046. Tumor Grade Associated Genomic Mutations in Chinese Patients with Lung Cancer

EP16.03-047. Genomic Landscape of Squamous Cell Carcinoma Lung in an Indian Cohort

EP16.04-001. The Role of Stromal PDGFR-activation in NSCLC

EP16.04-002. Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLC

EP16.04-003. High Dimensional Spatial Profiling of the NSCLC Tumour Microenvironment

EP16.04-004. Impact of Gender on Cellular Response to Cigarette Smoke Extract

EP16.04-005. Investigating the Side Effects of Docetaxel on Rat Lung and Heart

EP16.04-006. A Novel Orthotopic Xenograft Mouse Model to Study Lung Cancer-Associated Fibroblasts and Lymphangiogenesis

EP16.04-007. ALDH2 Downregulation, Aberrant DNA Methylation, and Loss of Stemness Pathways as an Enhanced Biomarker in Lung Adenocarcinoma

EP16.04-008. Cytotoxic Effects of Carnosic Acid Are Mediated by Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling in H1299 NSCLC Cells

EP16.04-009. The Proliferative Effect of 27-Hydroxycholesterol as a Selective Estrogen Receptor Modulator on Pathology of NSCLC

EP16.04-010. Histological and Genetic Parental Tumor Characteristics are Conserved in Patient-derived Non-small Cell Lung Cancer Organoids

EP16.04-011. Sex Hormone Signalling in Lung Adenocarcinoma Limits Tumour Virulence

EP16.04-012. Retrospective Analysis of Non-Small Cell Lung Cancer with Mucinous Histology Subtype

EP16.04-013. Spatial Multi-Omics Landscape of Radiologically Preinvasive/Invasive Lesion in Part-Solid Lung Adenocarcinoma

EP16.04-014. NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma

EP16.04-015. Chemotherapy Upregulates Programmed Cell Death Ligand 1 Expression in Non-Small Cell Lung Cancer Cell Lines and Patient-Derived Organoid Models

EP16.04-016. Overexpression of CEACAM6 Activates Src-FAK Signaling and Inhibits Anoikis, through Homophilic Interactions in Lung Adenocarcinomas

EP16.04-017. Lineage Switching and Tumor Microenvironment Roles of Tumor Suppressors in Autochthonous Lung Cancer Models

EP16.04-018. DNA Mismatch Repair in Lung Adenocarcinoma in Morocco

EP16.04-019. Impact of Chemotherapy on Tridimensional Multicellular Non-small Cell Lung Cancer Spheroids With Microenvironment Cells

EP16.04-020. Dysregulation of 14-3-3 Signaling Adapters in Lung Adenocarcinoma, New Insights Into the Impact on Cancer Cell Biology

EP16.04-021. Chromatin Remodeling Drives Lung Pre-malignancy and is a Target for Prevention

EP16.04-022. Prognosis of Epithelial-Mesenchymal Transition-Related lncRNA Profile in LUSC Patients

EP16.04-024. HMGB1-mediated Autophagy Promotes Gefitinib Resistance in Human Non-small Cell Lung Cancer

EP16.04-025. Statins Suppress SOAT1 Expression & Reduce Cholesterol Esterification in Statin-sensitive Lung Cancer Cells

EP16.04-026. Effectiveness of Atorvastatin and SR-12813 Combination in Statin-resistant and Statin-sensitive Lung Cancer Cell Lines

EP16.04-027. Identification of Optimal Internal Reference Gene to Analyze the Anticancer Effects of Statins in Lung Cancer Cells

EP16.04-028. PHLPP2 Regulates Ferroptosis Through Nrf2 Pathway to Affected Cell Cycle and Apoptosisin Lung Squamous Cell Carcinoma

EP16.04-029. Downregulation of PHLPP2 Induced by Radiation Promotes GPX4-mediated Ferroptosis Defense and Radioresistance in Lung Cancer

EP16.04-030. Cancer-Associated Fibroblasts Attenuate DNA Damage Repair by Promoting Glycolysis in Non-small Cell Lung Cancer

EP16.04-031. Connexin 43 Overexpression Induces Angiogenesis in Vitro Following Phosphorylation at Ser279 in its C Terminus

EP16.04-032. Indoleamine 2,3-dioxygenase 1 (IDO1) Blood Metabolites May Improve Predictive Accuracy for Radiation Pneumonitis

EP05.02-007. Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery - 2